intercure.co (INCR): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

This chart illustrates that the market value of InterCure Ltd. (INCR) relative to EBITDA is 0.00, highlighting the impact of Israel's strict licensing requirements on the business valuation. InterCure Ltd. (INCR) operates automated Israeli greenhouses to ensure a stable supply of raw materials. The company achieves operational efficiency by outsourcing logistics and promotion to external contractors, which minimizes costs when legislative norms change.

INCR InterCure: Enterprise Value to EBITDA Ratio in the range 11/23/2025 - 11/12/2026

intercure.co - analytical breakdowns and key metrics (INCR)

- current price and projected stock value:

Stock Price InterCure|INCR - Analyst Consensus Forecast

- stock exchange capitalization data:

Market Value INCR|INCR - Value Adjusted for Debt and Cash

- book value of equity indicators:

Net Assets per Single Share InterCure|INCR - Company Net Assets|Market Capitalization to Book Value Ratio intercure.co|INCR - Company Total Asset Base

- debt and solvency information:

- business earnings and investment ratios data:

INCR - Net Income|Future Profit InterCure Ltd.|INCR - P/E Multiple|Future Price to Earnings InterCure|INCR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple INCR|INCR - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months InterCure|INCR - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months intercure.co|INCR - Earnings per share growth in current year|Expected earnings per share growth for next year InterCure Ltd.

General company analysis:Canndoc INCR

To minimize risks when analyzing capital-intensive assets, it is necessary to evaluate the ratio of enterprise value to earnings before interest, taxes, depreciation, and amortization. The current EV/EBITDA multiple measures the business payback period inclusive of debt, which is critical for InterCure Ltd. (INCR) amid Israel's geopolitical instability, where cash flow resilience determines the company's ability to withstand regional shocks.

Competitor analysis

EV/EBITDA Multiple INDV (Indivior Group)|EV/EBITDA Multiple Collegium Corp COLL|CRON - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CGC (canopygrowth.com)|High Tide (HITI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Aurora Cannabis Inc.|ACHV (Achieve Life Sciences, Inc) - EV/EBITDA Multiple|skyebioscience.com (SKYE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Anebulo Pharmaceuticals (ANEB)|nutriband.com - Enterprise Value to Operating Income Before Depreciation|Nasus Pharma - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio IGC (India Globalization Capital)|MIRA Pharma - EV/EBITDA Multiple|Company Value to EBITDA Flora Growth Inc|imcannabis.com (IMCC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Adial Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|ARTL (Artelo Biosciences Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Ensysce (ENSC)|Enterprise Value to EBITDA Ratio TTNP (Titan Pharmaceuticals)|EV/EBITDA Multiple Greenlane Corp (GNLN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization InMed Pharmaceuticals INM|Business Value to Operating Income Before Depreciation AKAN|Enveric Biosciences, Inc. - EV/EBITDA Multiple|Company Value to EBITDA Bright Green|HPCO (Hempacco) - Enterprise Value to EBITDA Ratio